//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon


Online Registration is Open!
Register by Friday, February 26 to Save Up to $500!
»Pricing Chart

Add to Outlook Calendar

Find Another IBC Event

Bioconjugates: From Targets to Therapeutics


Transitioning Innovation into Viable Therapeutic Candidates

June 13-15, 2016
Parc 55 Hilton
San Francisco, CA

Speaker Interviews

Speaker Interviews

Pre-Show Speaker Interviews

Thank you for your interest in IBC's Bioconjugates: From Targets to Therapeutics event. To give you sneak peek at the caliber of the content presented at the conference - we would like to give you FREE access to these speaker interviews.

To Download: click the icon or the speaker name

Robert Lutz, Ph.D., Vice President, Translational Research and Development, ImmunoGen, Inc. At the event, Lutz will speak about:

  • The Evolution of ADCs: Lessons Learned from the Past. Where are We Going?
    This talk will cover what has been learned in the two decades of ADC clinical development. It will highlight the problems encountered with current technologies and discuss where new technologies, such as site directed conjugation, alternate scaffolds, and new payloads may provide answers (or new problems!).

» Download the Interview Transcript (PDF)

Carolyn R. Bertozzi, Ph.D., T.Z. and Irmgard Chu Distinguished Professor of Chemistry and Professor of Molecular and Cell Biology, UC Berkeley; Investigator, Howard Hughes Medical Institute; Senior Faculty Scientist, Lawrence Berkeley National Laboratory. At the event, Bertozzi will speak about:

  • Bioorthogonal Chemistries for Biomolecular Engineering
    Bioorthogonal chemical reactions have such exquisite selectivity that they can be employed to modify biomolecules even within the environs of live organisms. This presentation will focus on recent developments in bioorthogonal reaction methodology and applications to the production of chemically modified protein therapeutics such as antibody-drug conjugates. The use of bioorthogonal chemical reporters for in vivo imaging and disease biomarker discovery will also be discussed.

» Download the Interview Transcript (PDF)